Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy

Тенектеплаза при ишемическом инсульте через 4,5–24 часа без тромбэктомии
Hao Wang, Marc Fisher, Yongjun Wang, Bruce C.V. Campbell, Lihua Wang, Yuesong Pan, Chunmiao Duan, Shuangzhe Wu, Wanxing Ye, Manjun Hao, Mark William Parsons, Yunyun Xiong, Xintong Liu, Lee H. Schwamm, Fengyuan Che, Hongguo Dai, Yunyun Xiong, Meng Xia, Aoming Jin, Marc Fisher, Yong Jiang, Li Zhou, Yuming Xu, Chunxue Wang, Lixia Zong, Zefeng Tan, Ziran Wang, Zhixin Cao, Liyuan Wang, Hao Li, Zixiao Li, Xingquan Zhao, Anding Xu, Xia Meng, Lihua Wang, Yuming Xu
2024-06-14

Large-vessel occlusionLate-window thrombolysisModified Rankin ScalePerfusion imagingTenecteplase
BACKGROUND: Tenecteplase is an effective thrombolytic agent for eligible patients with stroke who are treated within 4.5 hours after the onset of stroke. However, data regarding the effectiveness of tenecteplase beyond 4.5 hours are limited. METHODS: In a trial conducted in China, we randomly assigned patients with large-vessel occlusion of the middle cerebral artery or internal carotid artery who had salvageable brain tissue as identified on perfusion imaging and who did not have access to endovascular thrombectomy to receive tenecteplase (at a dose of 0.25 mg per kilogram of body weight; maximum dose, 25 mg) or standard medical treatment 4.5 to 24 hours after the time that the patient was last known to be well (including after stroke on awakening and unwitnessed stroke). The primary outcome was the absence of disability, which was defined as a score of 0 or 1 on the modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability), at day 90. The key safety outcomes were symptomatic intracranial hemorrhage and death. RESULTS: A total of 516 patients were enrolled; 264 were randomly assigned to receive tenecteplase and 252 to receive standard medical treatment. Less than 2% of the patients (4 in the tenecteplase group and 5 in the standard-treatment group) underwent rescue endovascular thrombectomy. Treatment with tenecteplase resulted in a higher percentage of patients with a modified Rankin scale score of 0 or 1 at 90 days than standard medical treatment (33.0% vs. 24.2%; relative rate, 1.37; 95% confidence interval, 1.04 to 1.81; P = 0.03). Mortality at 90 days was 13.3% with tenecteplase and 13.1% with standard medical treatment, and the incidence of symptomatic intracranial hemorrhage within 36 hours after treatment was 3.0% and 0.8%, respectively. CONCLUSIONS: In this trial involving Chinese patients with ischemic stroke due to large-vessel occlusion, most of whom did not undergo endovascular thrombectomy, treatment with tenecteplase administered 4.5 to 24 hours after stroke onset resulted in less disability and similar survival as compared with standard medical treatment, and the incidence of symptomatic intracranial hemorrhage appeared to be higher. (Funded by the National Natural Science Foundation of China and others; TRACE-III ClinicalTrials.gov number, NCT05141305.).
1
Functional independence at 90 days occurred in 33.0% of tenecteplase-treated patients versus 24.2% receiving standard treatment (relative rate, 1.37; 95% CI, 1.04–1.81; P=0.03).
2
In Chinese patients with large-vessel occlusion and salvageable tissue 4.5–24 hours after last-known-well, tenecteplase improved 90-day functional independence versus standard medical treatment.
3
Ninety-day mortality was similar between tenecteplase and standard treatment: 13.3% versus 13.1%.
4
Symptomatic intracranial hemorrhage within 36 hours was more frequent with tenecteplase, occurring in 3.0% versus 0.8% with standard treatment.
5
The trial evaluated tenecteplase largely without thrombectomy: fewer than 2% of participants underwent rescue endovascular thrombectomy.

Chinese patients with ischemic stroke due to large-vessel occlusion of the middle cerebral artery or internal carotid artery, with salvageable brain tissue, treated 4.5 to 24 hours after they were last known to be well without access to endovascular thrombectomy

The efficacy and safety of tenecteplase versus standard medical treatment, assessed by 90-day functional independence, symptomatic intracranial hemorrhage, and mortality

Publication Details
Publication Date
2024-06-14
Journal
Publisher
ISSN
Cited by
252
Access Type
Author Information
Authors
Hao Wang
Marc Fisher
Yongjun Wang
Bruce C.V. Campbell
Lihua Wang
Yuesong Pan
Chunmiao Duan
Shuangzhe Wu
Wanxing Ye
Manjun Hao
Mark William Parsons
Yunyun Xiong
Xintong Liu
Lee H. Schwamm
Fengyuan Che
Hongguo Dai
Yunyun Xiong
Meng Xia
Aoming Jin
Marc Fisher
Yong Jiang
Li Zhou
Yuming Xu
Chunxue Wang
Lixia Zong
Zefeng Tan
Ziran Wang
Zhixin Cao
Liyuan Wang
Hao Li
Zixiao Li
Xingquan Zhao
Anding Xu
Xia Meng
Lihua Wang
Yuming Xu
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%